Compound heterozygous and digenic inheritance in early-onset Parkinson’s disease: a systematic review
9 affiliations
- 1Brain & Mental Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
- 2School of Biomedical Sciences, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, QLD, Australia
- 3Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Querétaro, Mexico
- 4Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
- 5Department of Neurology and Molecular Medicine Laboratory, Concord Repatriation General Hospital, Concord, NSW, Australia
- 6ANZAC Research Institute, University of Sydney, Sydney, NSW, Australia
- 7Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
- 8School of Clinical Medicine, UNSW Medicine & Health, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW, Sydney, NSW, Australia
- 9School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia
Abstract
Introduction: Compound heterozygous (CH) genotypes represent an established biallelic autosomal-recessive mechanism in early-onset Parkinson’s disease (EOPD), whereas digenic inheritance (DI) has been proposed for variant combinations across two genes but is more difficult to establish. We systematically evaluated the genetic architecture and clinical features of CH cases and cases reported as DI in the published literature.
Methods: This PRISMA-compliant systematic review included studies reporting CH or DI EOPD through September 2026. Two reviewers independently screened studies, extracted data, and curated variant- and case-level information. Variants were harmonized using current Human Genome Variation Society nomenclature and classified by gene, variant type, ancestry, and inheritance model.
Results: We included 106 studies comprising 304 CH and 16 DI cases. CH was dominated by PRKN, with structural variants present in 85% (205/241) of PRKN cases, predominantly exon-level deletions. PINK1 was the second most frequently implicated CH gene, whereas other CH subtypes were rare and genetically heterogeneous. Cases reported as DI involved seven genes, most commonly LRRK2–PRKN and PINK1–PRKN, although most variant combinations were unique. Across the CH and reported-DI groups, patients presented with a core Parkinsonian syndrome but showed substantial variability in age at onset, motor severity, and non-motor manifestations. PRKN-associated CH cases generally had earlier onset and favorable levodopa responsiveness, whereas PLA2G6- and VPS13C-associated cases more often exhibited cognitive impairment, psychiatric features, or structural neuroimaging abnormalities. No reproducible genotype-specific phenotype emerged.
Conclusion: Compound heterozygous represents a conventional biallelic recessive mechanism in EOPD and was largely driven by PRKN structural variation. In contrast, cases reported as DI were rare and heterogeneous, and the available evidence generally did not establish causal digenic inheritance. These findings support comprehensive detection of structural and sequence variants while highlighting the need for segregation, functional, and replication evidence to distinguish causal DI from modifier effects or coincidental variant co-occurrence.
Related
- Congenital hyperinsulinism as part of a multisystem disease caused by a compound heterozygous variant in the YARS1 gene
- A case of renal hypouricemia type 1 associated with compound heterozygous URAT1/SLC22A12 variants A209V and F379L: clinical evidence for their pathogenic significance
- Familial Hypomagnesemia With Hypercalciuria and Nephrocalcinosis: A Case Report of Compound Heterozygous Variants in the CLDN16 Gene Inherited From Symptomatic Heterozygous Carriers
- Case Report: Neonatal ultra-severe hemolytic anemia complicated by pulmonary hypertension induced by compound heterozygous variants in the KLF1 gene and literature review
- Novel compound heterozygous POLR3A variation: expanding 4H syndrome with progressive keratoconus.
BibTeX
@article{floresocampo2026compound,
title = {{Compound heterozygous and digenic inheritance in early-onset Parkinson’s disease: a systematic review}},
author = {Victor Flores-Ocampo and Grecia Sevilla-Parra and Fangyuan Cao and Deepak Darshan and Santiago Díaz-Torres and Claudia Gonzaga-Jauregui and Kishore Raj Kumar and Miguel Enrique Rentería and Natalia S. Ogonowski},
journal = {Frontiers in Aging Neuroscience},
year = {2026},
month = oct,
doi = {10.3389/fnagi.2026.1930518},
url = {https://doi.org/10.3389/fnagi.2026.1930518},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Compound heterozygous and digenic inheritance in early-onset Parkinson’s disease: a systematic review
AU - Victor Flores-Ocampo
AU - Grecia Sevilla-Parra
AU - Fangyuan Cao
AU - Deepak Darshan
AU - Santiago Díaz-Torres
AU - Claudia Gonzaga-Jauregui
AU - Kishore Raj Kumar
AU - Miguel Enrique Rentería
AU - Natalia S. Ogonowski
PY - 2026
DA - 2026/10/22
JO - Frontiers in Aging Neuroscience
DO - 10.3389/fnagi.2026.1930518
UR - https://doi.org/10.3389/fnagi.2026.1930518
AB - Introduction: Compound heterozygous (CH) genotypes represent an established biallelic autosomal-recessive mechanism in early-onset Parkinson’s disease (EOPD), whereas digenic inheritance (DI) has been proposed for variant combinations across two genes but is more difficult to establish. We systematically evaluated the genetic architecture and clinical features of CH cases and cases reported as DI in the published literature. Methods: This PRISMA-compliant systematic review included studies reporting CH or DI EOPD through September 2026. Two reviewers independently screened studies, extracted data, and curated variant- and case-level information. Variants were harmonized using current Human Genome Variation Society nomenclature and classified by gene, variant type, ancestry, and inheritance model. Results: We included 106 studies comprising 304 CH and 16 DI cases. CH was dominated by PRKN, with structural variants present in 85% (205/241) of PRKN cases, predominantly exon-level deletions. PINK1 was the second most frequently implicated CH gene, whereas other CH subtypes were rare and genetically heterogeneous. Cases reported as DI involved seven genes, most commonly LRRK2–PRKN and PINK1–PRKN, although most variant combinations were unique. Across the CH and reported-DI groups, patients presented with a core Parkinsonian syndrome but showed substantial variability in age at onset, motor severity, and non-motor manifestations. PRKN-associated CH cases generally had earlier onset and favorable levodopa responsiveness, whereas PLA2G6- and VPS13C-associated cases more often exhibited cognitive impairment, psychiatric features, or structural neuroimaging abnormalities. No reproducible genotype-specific phenotype emerged. Conclusion: Compound heterozygous represents a conventional biallelic recessive mechanism in EOPD and was largely driven by PRKN structural variation. In contrast, cases reported as DI were rare and heterogeneous, and the available evidence generally did not establish causal digenic inheritance. These findings support comprehensive detection of structural and sequence variants while highlighting the need for segregation, functional, and replication evidence to distinguish causal DI from modifier effects or coincidental variant co-occurrence.
SN - 1663-4365
ER -